OneChain Immunotherapeutics is a spin-off company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, focused on developing immunotherapies against haematological neoplasms using CAR-T technology. The company's primary goal is to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez. Specifically, the company plans to offer treatments based on immunotherapy for different tumours, such as cortical T-cell acute lymphoblastic leukaemia (coT-ALL), which will allow patients to receive treatment for haematological malignancies.